https://www.selleckchem.com/products/stf-31.html
8 months and not reached, respectively (p 0.0001). FOLFIRINOX for LAPA and BRPA seems to be effective with a manageable toxicity profile. These promising results in "real-life" patients now have to be confirmed in a Phase 3 randomised trial. FOLFIRINOX for LAPA and BRPA seems to be effective with a manageable toxicity profile. These promising results in "real-life" patients now have to be confirmed in a Phase 3 randomised trial.A recent Phase 1 clinical study of the immunological effects of inhibiting the chemokine receptor, CXCR4,
Like
Comment
Share
